Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Pipeline Review, H2 2016’, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aviara Pharmaceuticals Inc

Encycle Therapeutics

Genentech Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Overview 6

Therapeutics Development 7

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Stage of Development 7

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Therapy Area 8

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Indication 9

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Companies 12

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development 20

Aviara Pharmaceuticals Inc 20

Encycle Therapeutics 21

Genentech Inc 22

Protagonist Therapeutics Inc 23

Takeda Pharmaceutical Company Ltd 24

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles 25

etrolizumab - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

PTG-100 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Crohn's Disease and Ulcerative Colitis - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

vedolizumab - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Projects 36

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products 37

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Featured News & Press Releases 38

Dec 09, 2016: GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naive Patients with Moderately to Severely Active Crohns Disease 38

Dec 08, 2016: Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference 39

Nov 24, 2016: Takeda’s ENTYVIO (vedolizumab) receives positive reimburement recommendation from Common Drug Review for treatment of Crohns Disease 40

Nov 23, 2016: Takeda IBD Treatment ENTYVIO (vedolizumab) Receives Prestigious Prix Galien Canada Innovative Product Award 42

Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn’s Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting 43

Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies 44

Oct 13, 2016: Scientists at NIH and Emory achieve sustained SIV remission in monkeys 45

Oct 13, 2016: Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna 47

Oct 12, 2016: PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease Patients 47

Sep 28, 2016: Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis 48

Sep 16, 2016: Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 49

May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting 51

May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016 52

Mar 19, 2016: New Data Presented at European Crohn's and Colitis Organisation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment 52

Jan 08, 2016: Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Aviara Pharmaceuticals Inc, H2 2016 20

Pipeline by Encycle Therapeutics, H2 2016 21

Pipeline by Genentech Inc, H2 2016 22

Pipeline by Protagonist Therapeutics Inc, H2 2016 23

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 24

Dormant Projects, H2 2016 36

Discontinued Products, H2 2016 37

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports